BioSig Technologies Competitors

Edap Tms (NASDAQ:EDAP) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Earnings and Valuation

This table compares Edap Tms and BioSig Technologies' revenue, earnings per share and valuation.

Edap Tms has higher revenue and earnings than BioSig Technologies.

Volatility and Risk

Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.

Institutional & Insider Ownership

18.3% of BioSig Technologies shares are owned by institutional investors. 19.5% of BioSig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Edap Tms and BioSig Technologies, as provided by MarketBeat.com.

Edap Tms presently has a consensus price target of $12.50, suggesting a potential upside of 51.33%. Given Edap Tms' higher possible upside, research analysts plainly believe Edap Tms is more favorable than BioSig Technologies.

Profitability

This table compares Edap Tms and BioSig Technologies' net margins, return on equity and return on assets.

Summary

Edap Tms beats BioSig Technologies on 7 of the 10 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Volatility & Risk

BioSig Technologies has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 2.49, indicating that its stock price is 149% more volatile than the S&P 500.

Profitability

This table compares BioSig Technologies and Second Sight Medical Products' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioSig Technologies and Second Sight Medical Products, as reported by MarketBeat.

Earnings and Valuation

This table compares BioSig Technologies and Second Sight Medical Products' gross revenue, earnings per share and valuation.

Second Sight Medical Products has higher revenue and earnings than BioSig Technologies.

Institutional & Insider Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 4.1% of Second Sight Medical Products shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by company insiders. Comparatively, 67.5% of Second Sight Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Second Sight Medical Products beats BioSig Technologies on 4 of the 7 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares BioSig Technologies and FONAR's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares BioSig Technologies and FONAR's top-line revenue, earnings per share (EPS) and valuation.

FONAR has higher revenue and earnings than BioSig Technologies.

Volatility and Risk

BioSig Technologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for BioSig Technologies and FONAR, as reported by MarketBeat.

Institutional and Insider Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by insiders. Comparatively, 8.6% of FONAR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

FONAR beats BioSig Technologies on 6 of the 8 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for BioSig Technologies and IRIDEX, as provided by MarketBeat.com.

IRIDEX has a consensus price target of $6.50, suggesting a potential downside of 8.19%. Given IRIDEX's higher possible upside, analysts clearly believe IRIDEX is more favorable than BioSig Technologies.

Volatility and Risk

BioSig Technologies has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Institutional & Insider Ownership

18.3% of BioSig Technologies shares are owned by institutional investors. Comparatively, 32.6% of IRIDEX shares are owned by institutional investors. 19.5% of BioSig Technologies shares are owned by company insiders. Comparatively, 2.0% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares BioSig Technologies and IRIDEX's revenue, earnings per share and valuation.

IRIDEX has higher revenue and earnings than BioSig Technologies.

Profitability

This table compares BioSig Technologies and IRIDEX's net margins, return on equity and return on assets.

Summary

IRIDEX beats BioSig Technologies on 7 of the 10 factors compared between the two stocks.

ENDRA Life Sciences (NASDAQ:NDRA) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Earnings and Valuation

This table compares ENDRA Life Sciences and BioSig Technologies' gross revenue, earnings per share (EPS) and valuation.

ENDRA Life Sciences has higher revenue and earnings than BioSig Technologies.

Insider and Institutional Ownership

2.8% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 18.3% of BioSig Technologies shares are held by institutional investors. 9.6% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 19.5% of BioSig Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

ENDRA Life Sciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ENDRA Life Sciences and BioSig Technologies, as provided by MarketBeat.

Profitability

This table compares ENDRA Life Sciences and BioSig Technologies' net margins, return on equity and return on assets.

Summary

BioSig Technologies beats ENDRA Life Sciences on 5 of the 7 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares BioSig Technologies and Soleno Therapeutics' revenue, earnings per share (EPS) and valuation.

Risk & Volatility

BioSig Technologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Profitability

This table compares BioSig Technologies and Soleno Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for BioSig Technologies and Soleno Therapeutics, as reported by MarketBeat.com.

Soleno Therapeutics has a consensus target price of $8.6667, indicating a potential upside of 687.88%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than BioSig Technologies.

Insider and Institutional Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by insiders. Comparatively, 74.9% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Soleno Therapeutics beats BioSig Technologies on 7 of the 8 factors compared between the two stocks.